Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer to design, develop and commercialize diagnostic tests for therapeutic products across Pfizer’s pipeline. That pipeline includes 31projects in Phase I, 24 in Phase II, and 20 in Phase III as of November 2013. Under the agreement, Siemens will be one of Pfizer’s collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies. Siemens Clinical Laboratory (SCL), its "high-complexity" testing laboratory focused on advancing personalized medicine, will develop these companion diagnostic tests. “Companion diagnostics are an important enabler of targeted therapies for patients,” said John Hubbard, Senior Vice President and Worldwide Head of Development Operations at Pfizer. 

Siemens’ is known for providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development. The agreement is to leverage these capabilities.

News

Siemens Healthcare Diagnostics Inc. has entered into a master collaboration agreement with Pfizer